Compare PEB & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | PGEN |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | PEB | PGEN |
|---|---|---|
| Price | $14.11 | $4.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $12.59 | $8.33 |
| AVG Volume (30 Days) | 2.4M | ★ 5.6M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $2.25 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.56 | $1.23 |
| 52 Week High | $14.23 | $5.47 |
| Indicator | PEB | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 69.45 | 56.19 |
| Support Level | $10.21 | $4.02 |
| Resistance Level | N/A | $4.43 |
| Average True Range (ATR) | 0.34 | 0.28 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 96.00 | 76.85 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.